Despite animal testing being a controversial topic for many years, it is still widely used globally to assess the safety of products and test the efficacy of new treatments and products. In 2020, the United States was the world’s largest user of animals in research and testing, with around 20 million animals used research and testing, followed by China where it is estimated that around 16 million animals were used in research and testing in that year. Animal testing is used especially in the medical, cosmetic, and chemical industries.

Animal Testing in the EU

The European Union also reported some 9.4 million animals used research and testing as of 2020. Basic research, and translational and applied research are the two leading purposes of animal testing in the European Union. Mice represent the most commonly used animal in research and testing in the EU, representing almost half of all animals used in research and testing, followed by fish and rats.

Animal Testing in Great Britain

Animal testing in Great Britain was most common in basic scientific research on the nervous system and the immune system, and most procedures on animals for scientific experiments in that year in Great Britain were conducted by universities and medical schools. As in the EU, mice were the most commonly used animals in research and testing, followed by domestic fowl and rats.

In 2019, 797,546 animals were used for research in research facilities in the United States. This is an increase from the previous year, when about 780,070 animals were used for research in the country.

This statistic displays the total number of animals used in scientific research in the European Union from 2015 to 2022, including only animals used for the first time each year. In 2022, some 8.4 million animals were used in scientific research in all EU member states and Norway, an increase of over 400 thousand compared to the previous year.

USDA 2016 Data on Animal Testing in the United States

Broken down by State / Territory

Required Reporting by Testing Facilities in the US

Each USDA-registered research facility and Federal research facility is required by the Animal Welfare Act (AWA) to submit an Annual Report (APHIS Form 7023) that documents its use of animals for research, testing, teaching, experimentation, and/or surgery. USDA-APHIS Animal Care receives copy of each research facility’s annual report on or before December 1. Animal Care reviews the data to ensure the calculated totals are consistent with the number of reported animals in each pain/distress category. Reports with inconsistent data are returned to the research facility for correction. The completeness and accuracy of the non-Federal research facility annual reports might be validated during USDA animal welfare compliance inspections. However, research facilities sometimes include additional data on their annual reports that is not required under the Animal Welfare Act, such as data about rats of the genus rattus, mice of the genus mus, and birds bred for use in research, animals used in excluded field studies, animals used in clinical trials in the context of a veterinary client relationship, and reptiles, fish, or other animals that are not covered by the AWA.

Summary

The data in the summary reports represent the number of animals USDA-registered research facilities and Federal research facilities reported as being used or held for research, testing, teaching, experimentation, and/or surgery. The summary reports are based on the Annual Report column designations:

• Column B (animals held by a facility but not used in any research that year).

• Column C (animals used in research; no pain involved; no pain drugs administered).

• Column D (animals used in research; pain involved; pain drugs administered).

• Column E (animals used in research; pain involved; no pain drugs administered).

• ALL_PAINTYPES_2016 = (total number of animals used in research; Column C + Column D + Column E).

States include 50 states plus Puerto Rico (PR) and District of Columbia (DC).

Acknowledgements

USDA Animal and Plant Health Inspection Service More years found here: https://www.aphis.usda.gov/aphis/ourfocus/animalwelfare/sa_obtain_research_facility_annual_report/ct_research_facility_annual_summary_reports

Inspiration

The Beagle Freedom Project (Photo taken from there website)

The Humane Society

Peta

Bruna, Chewy, Cat Stevens, Remy, Owen, Neumann and Timmy (dogs and one cat).

This statistic shows the moral stance of Americans regarding medical testing on animals in 2018. During the survey, 54 percent of respondents stated that they think medical testing on animals is morally acceptable, while 2 percent said it depends.

This statistic displays the share of purposes for scientific research on animals in the 27 European Union countries (including Norway) in 2019. The main purpose for testing on animals was for basic research, with some 45 percent.

The objective of this study was to evaluate the safety and immunogenicity of a live, attenuated recombinant RVF arMP-12ΔNSm21/384 nucleotide deletion vaccine candidate in domestic ruminants. . The immunogenicity of 2 doses of 104 and 105 Tissue Culture Infectious Doses50% (TCID50) of the vaccine was assessed in of 2 groups of 10 sheep, 2 groups of 10 goats, and doses of 105 and 106 TCID50 were used to vaccinate 2 groups of 10 calves. The results showed that the immunogenicity among sheep, goats and cattle indicated that doses of 104 - 106 TCID50 elicited detectable antibody by day 7 post-vaccination and antibody titers that ranged from 1:14 to 1:305 on day 14 PV with sustained titers through day 28 PV. Overall, these findings indicated that the RVF arMP-12ΔNSm21/384 vaccine is a promising candidate for the prevention of RVF among domestic ruminants.

The global animal research and testing market is projected to reach a market size of USD XXX million by 2033, growing at a CAGR of XX% from 2023 to 2033. Key drivers of this growth include the rising prevalence of chronic diseases, the need for more accurate and reliable preclinical data, and the growing adoption of animal models in biomedical research. Additionally, the increasing demand for personalized medicine and the growing investment in drug discovery and development are expected to drive the market growth over the forecast period. Key trends in the animal research and testing market include the increasing adoption of genetically modified animal models, the adoption of non-animal models, and the use of artificial intelligence (AI) and machine learning (ML) to enhance research and testing processes. The growing focus on animal welfare and the ethical concerns associated with animal testing are also restraining the market growth. However, the increasing adoption of alternative methods, such as in vitro and in silico models, is expected to alleviate these concerns and drive the market growth. North America is the largest regional market for animal research and testing, followed by Europe and Asia Pacific. Asia Pacific is expected to experience the highest growth rate due to the increasing demand for animal models in biomedical research and the growing investment in drug discovery and development in the region.

This statistic shows the likelihood of consumers in the United States to stop purchasing from their favorite cosmetics/makeup brand if it were reported that the brand test their products on animals, as of April 2017. During the survey, 32 percent of consumers reported that they would very likely stop purchasing from their favorite brand if they tested on animals.

Abstract Integrity in animal research, coupled with scientific and social responsibility, demands rigor in the construction and execution of the protocol, commitment to the promotion of animal welfare and the dissemination of suitable data. Protocols for submitting projects to the Ethics Committee on Animal Use, editorial policies and dissemination of the methodology as tools to promote research integrity were analysed based on the questioning of the vulnerability of researchers not trained to fulfill this demand. The results supported the insertion of planning and dissemination of research as a parameter of integrity and adherence to the principle of 3R (Replacement, Reduction and Refinement) as a guide to the decision of how much and how and why to use animals in research. We verified the efficiency of the administrative and legal instrument as a promoter of reflection on technical, ethical, social and legal conception and society. These should be subsidized by the educational role of Bioethics, carried out by committees to mitigate vulnerabilities of the researcher.

The provided information includes: year, month, animal species, purpose, vaccine name, code, brand category, brand name, batch number, total dose, expiry date, and judgment field data.

Background: The harm benefit analysis (HBA) is the cornerstone of animal research regulation and is considered to be a key ethical safeguard for animals. The HBA involves weighing the anticipated benefits of animal research against its predicted harms to animals but there are doubts about how objective and accountable this process is.

Objectives: i. To explore the harms to animals involved in pre-clinical animal studies and to assess these against the benefits for humans accruing from these studies; ii. To test the feasibility of conducting this type of retrospective HBA.

Methods: Data on harms were systematically extracted from a sample of pre-clinical animal studies whose clinical relevance had already been investigated by comparing systematic reviews of the animal studies with systematic reviews of human studies for the same interventions (antifibrinolytics for haemorrhage, bisphosphonates for osteoporosis, corticosteroids for brain injury, Tirilazad for stroke, antenatal corticos...

The global market for animals used in research and testing is a significant and steadily growing sector, projected to reach a substantial size. While the provided data points to a 2025 market value of $3,361 million and a Compound Annual Growth Rate (CAGR) of 7% from 2019 to 2033, a deeper analysis reveals several key drivers. Increased investment in pharmaceutical and biomedical research, the rising prevalence of chronic diseases necessitating extensive pre-clinical trials, and the growing demand for advanced animal models are all contributing to this expansion. The market is segmented based on animal species (rodents, primates, etc.), research area (drug discovery, toxicology, etc.), and geographical distribution. Leading players like Charles River Laboratories, Envigo, and Taconic Biosciences hold substantial market shares, characterized by strong technological capabilities, extensive animal facilities, and global presence. However, ethical concerns surrounding animal welfare and the rising popularity of alternative testing methods such as in-vitro studies and computational modeling represent significant restraints to unbridled growth. Regulatory changes and increased scrutiny regarding the use of animals in research are also factors influencing market dynamics. The forecast period of 2025-2033 projects sustained growth driven by continuing advancements in life sciences and the need for robust pre-clinical testing for novel therapies. The market's geographical distribution likely reflects the concentration of pharmaceutical and biotechnology companies, with regions like North America and Europe expected to dominate due to well-established research infrastructure and stringent regulatory frameworks. Emerging markets in Asia and other regions are anticipated to demonstrate accelerated growth, particularly driven by increasing government investment in R&D and expanding local pharmaceutical industries. Competitive intensity among the key players is likely to remain high, with ongoing innovation in animal model development, improved animal care practices, and strategic partnerships shaping the landscape. The future trajectory suggests a gradual shift towards more sophisticated animal models and increased adoption of the 3Rs principle (Replacement, Reduction, Refinement) in animal research. This principle aims to minimize the use of animals while maintaining the scientific rigor necessary for drug development and other research areas.

Incidents responded to by the Baton Rouge Animal Control and Rescue Center (ACRC). ACRC is responsible for carrying out duties related to animal-related situations, including: administering the anti-rabies vaccination, licensing, and tag program; investigating animal cruelty incidents; investigating dog fighting; resolving dangerous animal situations; rescuing injured animals; investigating abandoned animal cases; investigating occult, animal sacrifice, and bestiality cases; resolving stray animal situations; enforcing the leash law and owned animal problems; assisting law enforcement with narcotics, evictions, and DWI cases; enforcing barking dog cases; inspecting dog yards/pens; chaining or tethering compliance; assisting animal welfare groups with feral interventions; and conducting educational programs. As many of the incidents included within this data set involve active cases that are currently under investigation and computerized system limitations do not allow for automated screening of open/closed cases, the identity of animal owners is redacted to protect the privacy of the animal owner. Members of the public interested in the identity of a specific incident may contact ACRC directly to inquire about the incident and, if it is closed, ACRC will release a copy of the file to the person requesting it. However, location data regarding where the incident was reported or occurred is included within this data set, which may or may not be the same location as the animal owner's home or property. In addition, to protect the identity of the complainant (person filing the complaint or alerting ACRC to a potential incident), only the complainant's street name is included as part of this data set. Finally, while all incidents are updated on a daily basis, incidents involving animal cruelty are updated based on a rolling 30-day delay to allow for ACRC to investigate the incident and make a determination as to the validity of the cruelty complaint.

This is the official test set of the CLEF eHealth 2019, Task 1 - Multilingual Information Extraction (http://clef-ehealth.org/). It contains 407 non-technical summaries (NTS) of animal experiments planned to be carried out in Germany and originally online available at the AnimalTestInfo database (http://animaltestinfo.de). Each NTS contains a title, benefits (goals) of the experiments, possible harms caused to the animals, and comments about replacement, reduction and refinement (in the scope of the 3R principles). All documents are in the German language. The dataset includes the ICD-10 codes manually assigned by experts to the NTS. However, some NTSs have no ICD-10 codes assigned to them, as the codes were not applicable to the uses described in the NTS. All codes are chapters or groups from the ICD-10 German Modification 2016 version (https://www.dimdi.de/static/de/klassifikationen/icd/icd-10-gm/kode-suche/htmlgm2016/).

In this observational meta-science study, we surveyed a random sample of published animal experiments from 2011 to 2016 where interventions were applied to parents but effects examined in the offspring. We assessed whether entity–intervention pairs that contributed to the sample size (N) constituted true replication or pseudo replication. We found that only 22% of studies replicated the correct entity–intervention pair.